Top Tweets for #UpperGi
We are proud to announce the RCSEd-BBUGSS collaboration webinar: "Novel Therapies for Reflux Disease: Surgical versus Non-Surgical."
🗓 Tuesday, 7th July 2026
⏰ 19:00 – 20:00 BST
Register via the link below! 👇
🔗 https://t.co/xrfsDg2SOy
#RCSEd #BBUGSS #RefluxDisease #UpperGI
🚨Submission deadline extended to 25 January 2027!
Special Issue: "Clinical Updates on Personalized Upper #Gastrointestinal Surgery"
🌀Read more and submit your work here: https://t.co/poi8gdOpCF
Welcome your contributions!
#mdpijpm #UpperGI #Gastrointestinal #Surgery
🔎 #UpperGI surgery is rapidly evolving. (@OncoAlert)
Dr. John Herrera reviews key studies shaping surgical decision-making in gastric, GEJ, and esophageal cancers—from intrathoracic anastomosis to ICG-guided lymphadenectomy and emerging prehabilitation strategies.
🎥 Watch on #Vumedi: https://t.co/O3xIxQ3Jnw
#GIOncology #GastricCancer #EsophagealCancer #SurgicalOncology
🚨 After total gastrectomy, most oesophagojejunostomy leaks happen on ONE side.
In a high-volume centre series, 84.6% were right-sided—an anatomical “Achilles’ heel” with major ICU + LOS impact.
Read: https://t.co/ZhceDPAtwd
#GastricCancer #Surgery #UpperGI #GastroTwitter
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @my_ueg @AmCollSurgeons @JAMASurgery @AcademicSurgery @Surg_Education
Join us today for an exciting showcase of Olympus' #AI for #UpperGI, CADU and the latest #LowerGI features, CADDIE with @DrOmerAhmad during the Clinical Practice Symposium: “Doing More. Doing Less.” from 13:15–17:00!🚀
Secure your spot!
👉https://t.co/IUklngTUSw
@GastroLearn
📢 #LLE2026 kicks off today!
Join @DrOmerAhmad tomorrow from 13:15 - 17:00 at the Clinical Practice Symposium, "Doing More. Doing Less."
Discover Olympus' latest #AI for #UpperGI, CADU and the new #LowerGI features with CADDIE!🚀
👉https://t.co/IUklngTUSw
@GastroLearn
💟 February is Oesophageal cancer awareness month
https://t.co/u77HRm9Gjt
Read the 🆕 blog and check out 6️⃣ of the most important studies published in @bjsurgery and @bjsopen from the past year
#Cancer #Awareness #surgery #uppergi
📢 Review of Recent RCTs in Leading Surgical Journals
➡️ https://t.co/HAgWE9Kva9
🤿 Dive into our latest #RandomizedClinicalTrials review
🧠 Explore insights in: #Hernia | #Colorectal | #UpperGI | #HPB | #BreastSurgery
Don’t miss it!
Part II of #GIoncology series hosted by @_backtableONC & @jonmizrahi where we discuss updates in #upperGI malignancies including #MATTERHORN, #PD-L1 status implications on #FLOT-D, FORTITUDE-101/102, & LEAP 014/015
https://t.co/i4bRCPGous
@OncoAlert
What might treatment look like beyond standard FLOT chemotherapy for GI malignancies? In Part II of our ESMO 2025 recap, Dr. Jun Gong and Dr. Jonathan Mizrahi break down what key trials like MATTERHORN and FORITTUDE-10 actually mean for day-to-day management of gastroesophageal cancers—covering efficacy signals and how (and when) these data change your practice.
Listen here: https://t.co/TFpj74VVeC
#Oncology #ESMO2025 #GastroesophagealCancers #GIOncology #ClinicalTrials #PerioperativeChemotherapy
Fantastic first day at the #COSAIPOS2025 conference in Adelaide, learning from worldwide colleagues about #cancercare & hearing the #upperGI & #hepatobiliary cancers clinical update 💜 @COSAoncology @IPOSPsychoOncol @NIPANC_
📊 #UpperGIFRiday
Minimally invasive & robotic-assisted esophagectomy (MIE/RAMIE) are rapidly replacing open surgery—with no compromise in survival or outcomes.
📈 National data confirm improved adoption & safety.
Read more 👉 https://t.co/pTFMtmDlCH
#UpperGI @SurgEndosc
#ESMO25 #UpperGI
Temab-A (ABBV-400, Phase I)
c-Met–targeting ADC (Temab-A) in advanced PDAC
📊 ORR 24% overall | 40% post 1L gem–nab-paclitaxel | mPFS 5.3 mo
💊 G≥3 AEs: anemia 38%, neutropenia 21% | ILD 4.8%
✅ Promising early efficacy
@OncoAlert
#ESMO25 #UpperGI
VIRAGE (Phase IIb)
VCN-01 + gem/nab-paclitaxel vs GA alone in mPDAC
📈 mOS 10.8 vs 8.6 mo (HR 0.57; p=0.055) | mPFS 7.0 vs 4.6 mo (p=0.011)
💊 Well tolerated; transient flu-like & liver AEs
✅ Improved OS, PFS & DoR; meets primary endpoint
@myESMO @OncoAlert
#ESMO #UpperGI
CASSANDRA (Phase III)
Short vs long preop CT (PAXG/mFOLFIRINOX) in resectable/borderline PDAC
📊 mEFS 13.6 vs 13.0 mo (ns) | pCR 5% vs 0% | N0 44% vs 26%
✅ Longer CT increased pathological responses | No EFS/OS difference
@OncoAlert
#ESMO25 #UpperGI
Tinengotinib (Pooled FGFRi-refractory CCA)
Novel FGFR inhibitor overcoming FGFRi resistance
📈 mPFS 7.3 mo | mOS 15.9 mo | FGFRi-pretreated mPFS 5.6 mo, mOS 17.1 mo
💊 G3/4 AE 57% (HTN, PPE, diarrhea) | No G5
✅ Promising efficacy in FGFR2-altered
@OncoAlert
#ESMO25 #UpperGI
IMMUNOBIL (Phase II)
Durvalumab + tremelimumab (STRIDE) in pretreated BTC
📊 6-mo OS 58% | mOS 6.7 mo | ORR 12% | DCR 29%
💊 Gr≥3 TRAE 17% | PD-L1 ≥5 linked to better OS (12.8 vs 6.4 mo)
⚠️ Primary endpoint narrowly missed but activity seen in subsets
@OncoAlert
#ESMO25 #UpperGI
ZSAB-neoGOLP (Phase II–III)
Neoadjuvant GEMOX + lenvatinib + toripalimab in resectable high-risk iCCA
📊 mEFS 18.0 vs 8.7 mo | HR 0.48 (p=0.0006)
🧬 ORR 55% | MPR 19% | pCR 5%
✅ Statistically superior EFS and trend toward OS benefit
@OncoAlert
#ESMO25 #UpperGI
TALENTop (Phase III)
Liver resection vs continued atezo/bev after response/stable disease
📈 mTTF 20.4 vs 11.8 mo | HR 0.60 (p=0.015)
💊 Gr≥3 AE: 28% vs 21% | Surgical complications 22%
✅ Resection after response to atezo/bev improved outcomes vs continuation
@OncoAlert
#ESMO25 #UpperGI
ABC-HCC (Phase IIIb)
Atezolizumab + bevacizumab vs TACE in intermediate HCC
📊 mTTFS 14.6 vs 9.5 mo | HR 0.55 (95% CI 0.36–0.83)
💊 Manageable safety | Trial to continue to 2nd IA
✅ First randomized evidence favoring systemic Tx over TACE in BCLC-B
@OncoAlert
🚨 Don’t miss! #ESMO25 | #UpperGI
Mini Oral Session 2
🕣 08:30–10:00
1️⃣ IKF-035/ABC-HCC: Atezo + Bev vs TACE in intermediate HCC (Phase IIIb)
2️⃣ TALENTop: Resection vs continued Atezo/Bev in locally advanced HCC (Phase III)
3️⃣ Toripalimab + Lenvatinib + GEMOX: Neoadjuvant combo in high-risk resectable iCCA (Phase II–III)
4️⃣ IMMUNOBIL D18-1 PRODIGE-57: Durva + Treme post-platinum BTC (Phase II)
5️⃣ Tinengotinib: FGFRi-refractory CCA (pooled survival/safety data)
6️⃣ LBA85: Short vs long preop chemo in resectable PDAC (Phase III)
7️⃣ VIRAGE: VCN-01 + gem/nab-paclitaxel in mPDAC (Phase IIb)
8️⃣ ABBV-400: Anti–c-Met ADC in PDAC (Phase I)
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.6M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.7M followers
Taylor Swift
@taylorswift13
81.5M followers
Lady Gaga
@ladygaga
73M followers
Virat Kohli
@imvkohli
69.9M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.6M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.8M followers